Clinical Trials Browser

NCT07504588 2026-06-03

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

Phase 2 Not yet recruiting

87 enrolled

Gynecologic

Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma

NCT07178730 2026-05-06

ADAPT-TN-IV

Phase 3 Not yet recruiting

765 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07438600 2026-03-27

TianjinCIH

Phase 2 Not yet recruiting

38 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07393555 2026-02-06

Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)

Phase 2 Not yet recruiting

117 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07367178 2026-01-28

SATROPIN

Phase 2 Not yet recruiting

30 enrolled

Breast

Breast Neoplasms

NCT07368543 2026-01-28

STORM

Phase 2 Not yet recruiting

216 enrolled

Breast

Breast Neoplasms

NCT07299409 2025-12-23

First-Line Sacituzumab Govitecan in Advanced Untreated Triple-Negative Breast Cancer Patients.

Phase 2 Not yet recruiting

24 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07163481 2025-09-16

SoGreat

Phase 1 Not yet recruiting

12 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT07040644 2025-09-08

A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC

Phase 2 Not yet recruiting

150 enrolled

Breast

Triple Negative Breast Neoplasms

NCT07151586 2025-09-03

ALTER

Phase 2 Not yet recruiting

260 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms